Språk: en

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, RUSSIA, BELARUS OR IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION OR WOULD REQUITE FURTHER REGISTRATION OR OTHER MEASURES ABOVE WHAT IS REQUIRED BY SWEDISH LAW. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE.

NB: This is an English convenience translation of this press release. In case of any discrepancy, the correct version is the Swedish original “Stayble Therapeutics AB erhåller ytterligare toppgarantier I pågående företrädesemission”.

Stayble Therapeutics AB (”Stayble” or ”the Company”) hereby informs that the Company has received additional top-down underwriting commitment regarding the ongoing rights issue from professional investors equal to approximately MSEK 1.7. Thus, the rights issue is cover up to approximately 90 percent (approximately MSEK 31.7 by pre-subscription and underwriting commitments.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, RUSSIA, BELARUS OR IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION OR WOULD REQUITE FURTHER REGISTRATION OR OTHER MEASURES ABOVE WHAT IS REQUIRED BY SWEDISH LAW. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE.

NB: This is an English convenience translation of this press release. In case of any discrepancy, the correct version is the Swedish original “Stayble Therapeutics AB offentliggör prospect med anledning av företrädesemissionen”.

Today, March 24th, 2023, the subscription period of Stayble Therapeutics AB’s (”Stayble” or ”the Company”) rights issue of shares with preferential right for existing shareholders (“the Rights Issue”). The public is also invited to subscribe for shares. The subscription period lasts up to and including April 12th, 2023. The Rights Issue, if fully subscribed, can provide the Company a maximum of approximately MSEK 35.2, before deduction of transaction related costs. Prospectus and a teaser summary are available at the Company’s (www.staybletherapeutics.com), Sedermera Corporate Finance AB’s (www.sedermera.se) and Nordic Issuing AB’s (www.nordic-issuing.se) respective web pages. The investment documents are also available at Stayble’s web page for the Rights Issue (https://www.foretradesemission.staybletherapeutics.se/).

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, RUSSIA, BELARUS OR IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION OR WOULD REQUITE FURTHER REGISTRATION OR OTHER MEASURES ABOVE WHAT IS REQUIRED BY SWEDISH LAW. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE.

NB: This is an English convenience translation of this press release. In case of any discrepancy, the correct version is the Swedish original “Stayble Therapeutics AB erhåller ytterligare teckningsförbindelser och vederlagsfri toppgaranti I förestående företrädesemission”.

Stayble Therapeutics AB (”Stayble” or ”the Company”) hereby informs that the Company has received additional pre-subscription commitments as well as an additional remuneration-free top-down underwriting commitment regarding the upcoming rights issue from the Company’s single largest shareholders Chalmers Ventures AB, Robert Joki and Almi Invest Västsverige AB equal to approximately 3.7 MSEK. Through the remuneration-free top-down underwriting commitment by Almi Invest Västsverige AB, the rights issue is cover up to approximately 85 percent (approximately MSEK 30) by pre-subscription and underwriting commitments.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, RUSSIA, BELARUS OR IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION OR WOULD REQUITE FURTHER REGISTRATION OR OTHER MEASURES ABOVE WHAT IS REQUIRED BY SWEDISH LAW. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE.

NB: This is an English convenience translation of this press release. In case of any discrepancy, the correct version is the Swedish original “Stayble Therapeutics AB offentliggör prospect med anledning av företrädesemissionen”.

Today, March 17th, 2023, the Board of Directors of Stayble Therapeutics AB (“Stayble” or the “Company”) publishes the prospectus relating to the Company’s upcoming rights issue of shares, for which the subscription period starts on Friday, March 24th, 2023 (the “Rights Issue”). The prospectus has today been approved and registered by Swedish Financial Supervisory Authority and will be made available on the Swedish Financial Supervisory Authority’s website (www.fi.se). The prospectus is also available, starting today, on the websites of the Company (www.staybletherapeutics.com), Sedermera Corporate Finance AB (www.sedermera.se) and Nordic Issuing AB (www.nordic-issuing.se).

Idag den 16 mars 2023 hölls extra bolagsstämma i Stayble Therapeutics AB. Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades med erforderlig majoritet.

Stayble Therapeutics AB (“Stayble” or “the Company”) announces that the Company will participate in the annual Life-Science Day in Gothenburg, Sweden, which takes place on Wednesday, March 8, 2023. Andreas Gerward, CEO of Stayble, will present the company and introduce the newly started project with STA363, for patients suffering from disc herniation.

Stayble Therapeutics AB (“Stayble” or the “Company”) announces today that the Company has received approval to initiate the first clinical trial of its disc herniation candidate. The Company is broadening its activities by initiating a new project with STA363, targeting the indication lumbar disc herniation (“LDH”). A Phase 2b clinical trial is already underway in the indication degenerative disc disease (“DDD”).

Aktieägarna i Stayble Therapeutics AB, org.nr: 559024–8372, kallas härmed till extra bolagsstämma torsdagen den 16 mars 2023 kl. 14.00 i på bolagets kontor, Arvid Hedvalls Backe 4, Göteborg.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, RUSSIA, BELARUS OR IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION OR WOULD REQUITE FURTHER REGISTRATION OR OTHER MEASURES ABOVE WHAT IS REQUIRED BY SWEDISH LAW. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE.

Stayble Therapeutics AB, (”Stayble” or ”the Company”) announces that the Board of Directors has resolved on a new issue of shares, with preferential rights for existing shareholders, for a maximum amount of approximately MSEK 35.2 before deduction of transaction related costs (“the Rights Issue”). The decision made by the Board of Directors is subject to approval of an extraordinary general meeting, planned to be held on March 16th 2023. Notice to the extraordinary general meeting of shareholders will be announced by a separate press release. The purpose of the Rights Issue is to provide the Company with funds for operating costs and to initiate a phase 1b clinical study of the pharmaceutical candidate STA363 towards the new indication lumbar disc herniation, where the Board sees a great potential. Furthermore, the Rights Issue is planned to finance the completion of the current phase 2b clinical study towards the indication degenerative disc disease and to prepare the organization for partnerships. The Rights Issue is covered up to 80 percent by underwriting and pre-subscription commitments by the Board of Directors, management, principal owners, other existent shareholders and external professional investors.

Stayble Therapeutics AB (“Stayble” or the “Company”) hereby publishes its year-end report for 2022. The report is available as an attached document and on the Company’s website, https://staybletherapeutics.com/investor-relations/financial-reports/. Below is a summary of the report.

Stayble Therapeutics AB (“Stayble” or the “Company”) announces today that the Company’s Phase IIb study has reached the follow-up goal of 100 patients completing their 6-month visit. As a result, all necessary data to evaluate the study’s primary efficacy endpoint has been secured. All patients will continue to be followed until they complete their 12-month visit after which the code will be broken if the treatment is effective. To date, approximately 50 percent of patients have completed their 12-month visit. Top-line data is expected to be presented in Q4 2023.

Stayble Therapeutics AB (“Stayble” or the “Company”) announces that the Company’s ongoing Phase 2b study has been accepted for poster presentation at the 4th European Congress on Clinical Trials in Pain (SOPATE2022). The Congress will be held in Vienna, Austria, on December 7-8, 2022.

On Thursday, December 1, Stayble Therapeutics AB (“Stayble” or the “Company”) will participate in ProHearing’s investor event. The Company’s CEO, Andreas Gerward, will give an investor presentation and answer questions in a moderated Q&A session following the presentation.

Stayble Therapeutics AB (“Stayble” or the “Company”) hereby publishes the interim report for the third quarter of 2022. The report is available as an attached document and on the Company’s website.

Andreas Gerward, CEO of Stayble Therapeutics AB, will attend Stora Aktiedagen in Gothenburg on 8 November 2022. Topics to be discussed include Stayble’s market potential, the ongoing Phase IIb study and the way forward with ongoing partner discussions and the regulatory preparations for the Phase III study.

Stayble Therapeutics AB (“Stayble” or the “Company”) provides an update on the ongoing Phase IIb study. The company sees continued good compliance and approx. 70% of all patients have completed their 6-month follow-up, which is the primary endpoint of the study. Furthermore, Stayble is following the development in Russia and the assessment is that patients can conduct their follow-up visits without any difficulties.

Stayble Therapeutics AB (“Stayble” or the “Company”) has recently entered into an agreement with the analysis company Kalqyl AB (“Kalqyl”) which has now published the first analysis of Stayble.

Stayble Therapeutics AB (”Stayble” or the ”Company”) announces today that the Company’s CEO Andreas Gerward has purchased 15,000 shares in the Company for a total value of 73 350 SEK. The shares have been purchased in the open market.

Stayble Therapeutics AB (“Stayble” or the “Company”) announces today that the last patient has been recruited in the ongoing phase IIb clinical trial of STA363 for chronic disc-related low back pain. Recruitment is thereby completed. The patients will be followed for 12 months after inclusion. Final results from the study are expected to be available in Q4 2023 after the Company has compiled and analyzed data from all treated patients in the study.

Stayble Therapeutics AB (“Stayble” or the “Company”) hereby publishes the half-year report for 2022. The report is available as an attached document and on the Company’s website.